Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw et al.|New England Journal of Medicine|2019Cited by 6k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Jonathan Emberson et al.|The Lancet|2022Cited by 969
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policyAdeera Levin, Chih-Wei Yang, Robert G. Nelson et al.|The Lancet|2017Cited by 923
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisBrendon L. Neuen, Meg Jardine, T. Kue Young et al.|The Lancet Diabetes & Endocrinology|2019Cited by 870
Chronic Kidney Disease and Coronary Artery DiseaseMark J. Sarnak, Rukshana Shroff, Kerstin Amann et al.|Journal of the American College of Cardiology|2019Cited by 716